<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02355210</url>
  </required_header>
  <id_info>
    <org_study_id>USDA-NIFA-AFRI-003397</org_study_id>
    <nct_id>NCT02355210</nct_id>
  </id_info>
  <brief_title>Use of a Novel Synbiotic to Change Human Gut Bacteria and Improve Health in Obese Adults</brief_title>
  <official_title>Application of a Novel Synbiotic to Modulate the Human Gut Microbiota and Improve Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Nebraska Lincoln</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of a dietary supplement to improve gut health. The
      participants will take one of six dietary treatments for three weeks, and the gut bacteria
      and the gut intestinal barrier will be assessed to determine if these dietary treatments
      beneficially change these markers of gut health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, we intend to test the ecological and therapeutic functionality of a synbiotic
      combination of a Bifidobacterium adolescentis strain and the prebiotic galactooligosaccharide
      (GOS) in a human clinical trial. The synbiotic combination was selected based on a novel in
      vivo selection; specifically, the strain (BD1) is an human autochthonous gut organism that
      was enriched in an individual by GOS. Our experiments will test the efficacy of this
      synbiotic compared to a conventional synbiotic. We hypothesize this rationally selected
      synbiotic will improve intestinal barrier function in obese adult subjects, thereby
      preventing endotoxemia and metabolic inflammation, physiologically relevant functions that
      are increased in obese individuals. Our objectives are to: (1) compare the ability of the
      test and control synbiotic preparations to alter the gut microbiota in obese individuals; (2)
      test if GOS supports colonization and metabolic activity of test and control strains in the
      human gut; (3) compare the ability of the two synbiotic preparations to improve intestinal
      permeability and endotoxemia in obese subjects; and (4) assess associations between the gut
      microbiota and the test strain with biomarkers for translocation and endotoxemia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in microbiota, as measured by change in microbiota composition, including presence of B. adolescentis BD1 and B. animalis supsp lactis BB-12</measure>
    <time_frame>baseline and three weeks</time_frame>
    <description>change in microbiota composition, including presence of B. adolescentis BD1 and B. animalis supsp lactis BB-12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in intestinal permeability as measured by change in percent sugars in urine</measure>
    <time_frame>baseline and three weeks</time_frame>
    <description>change in percent sugars in urine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endotoxemia, as measured by change in circulating endotoxin by lipopolysaccharide and lipopolysaccharide-binding protein</measure>
    <time_frame>baseline and three weeks</time_frame>
    <description>change in circulating endotoxin by lipopolysaccharide and lipopolysaccharide-binding protein</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Intestinal Microbiota and Barrier Function</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 g lactose given as a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bifidobacteria adolescentis BD1, 10^9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bifidobacteria animalis subsp. lactis BB-12, 10^9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prebiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>galactooligosaccaride, 5 g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synbiotic 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>galacto-oligosaccharide (5 g) and Bifidobacteria adolescentis BD1 (10^9)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synbiotic 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>galacto-oligosaccharide (5 g) and Bifidobacteria animalis subsp. lactis BB-12 (10^9)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacteria adolescentis BD1</intervention_name>
    <description>packet containing 10^9 cells of Bifidobacteria adolescentis BD1</description>
    <arm_group_label>Probiotic 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacteria animalis subsp. lactis BB-12</intervention_name>
    <description>packet containing 10^9 cells of Bifidobacteria animalis subsp. lactis BB-12</description>
    <arm_group_label>Probiotic 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacteria adolescentis BD1 and galactooligosaccharide</intervention_name>
    <description>packet containing 10^9 cells Bifidobacteria adolescentis BD1 and 5 g galactooligosaccharide</description>
    <arm_group_label>Synbiotic 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide</intervention_name>
    <description>packet containing 10^9 cells B animalis subsp. lactis BB-12 and 5 g galactooligosaccharide</description>
    <arm_group_label>Synbiotic 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>galactooligosaccharide</intervention_name>
    <description>5 g galactooligosaccharide</description>
    <arm_group_label>Prebiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>lactose powder, 5 grams</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 yrs, obese (30 kg/m2 and greater)

        Exclusion Criteria:

          -  (1) prior intestinal resection, (2) patient history of GI diseases except for hiatal
             hernia, GERD, hemorrhoids, (3) severe renal disease defined by creatinine more than
             twice normal, (4) markedly abnormal liver function defined by ALT/AST over 4 times
             normal levels or elevated bilirubin (5) antibiotic use within the last 12 weeks prior
             to enrollment, (6) lean or overweight (BMI &lt; 30 kg/m2), (7) intolerant to aspirin, (8)
             regular use of aspirin, (9) excessive alcohol intake (&gt;2 drinks for men, 1 drink for
             women daily), (10) presence of uncontrolled chronic metabolic disease (cardiovascular
             disease, insulin requiring diabetes or uncontrolled diabetes, cancer, etc, (11) a plan
             to have a major change in dietary habit during the following 6 months, (12)
             consumption of probiotics, prebiotics or synbiotics without an appropriate 4 week
             washout period, (13) lactose intolerance or malabsorption; (14) subjects younger than
             18 or older than 65, (15) unwillingness to consent to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Hutkins, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska Lincoln</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Walter, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2015</study_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Heather Rasmussen, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>DEFB1 protein, human</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

